Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis
Siebert S, Coates L, Schett G, Raychaudhuri S, Chen W, Gao S, Seridi L, Chakravarty S, Shawi M, Lavie F, Sharaf M, Zimmermann M, Kollmeier A, Xu X, Rahman P, Mease P, Deodhar A. Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis. Arthritis & Rheumatology 2024, 76: 894-904. PMID: 38253404, DOI: 10.1002/art.42803.Peer-Reviewed Original ResearchBD-2 levelsTNFi-IRIL-23 signalingIL-22Clinical responseIL-17AInadequate response to tumor necrosis factor inhibitorsResponse to tumor necrosis factor inhibitorsTumor necrosis factor inhibitorsAmerican College of Rheumatology criteriaBiomarker levelsTNFi-IR patientsBD-2Serum biomarker levelsC-reactive proteinBaseline biomarker levelsActive PsAFactor inhibitorsPsA patientsWeek-24ACR20 respondersGuselkumabIL-17FRheumatology criteriaPharmacodynamic effectsCorrelation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial
Siebert S, Schett G, Raychaudhuri S, Guma M, Chen W, Gao S, Chakravarty S, Lavie F, Rahman P. Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial. Therapeutic Advances In Musculoskeletal Disease 2024, 16: 1759720x241283536. PMID: 39493888, PMCID: PMC11528637, DOI: 10.1177/1759720x241283536.Peer-Reviewed Original ResearchActive psoriatic arthritisDisease activityPharmacodynamic effectsC1MActive PsADISCOVER-2Psoriatic arthritisIL-6Phase III randomized controlled trialsAmerican College of Rheumatology response criteriaBiomarker levelsBD-2 levelsC1M levelsAssociated with durable improvementsJoint disease activityOverall disease activityEffect of guselkumabSerum biomarker dataM levelsC6M levelsRandomized controlled trialsFollow-up timepointsClinical responseACR50 responseIL-17A